Treatment of mouse carcinoma in vivo with a prostaglandin E2 analogue and indomethacin
1985

Effects of Prostaglandin E2 Analogue and Indomethacin on Mouse Carcinoma

Sample size: 38 publication Evidence: moderate

Author Information

Author(s): A. Bennett, M.A. Carroll, P.B. Melhuish, I.F. Stamford

Primary Institution: King's College School of Medicine and Dentistry

Hypothesis

If the antitumour effect of indomethacin is due to inhibition of PGE2 synthesis, then administration of a PGE2 analogue would be likely to produce an opposite response.

Conclusion

Indomethacin increased survival in mice with NC carcinoma, while the PGE2 analogue di-me-PGE2 counteracted this effect.

Supporting Evidence

  • Indomethacin-treated mice survived longer than controls.
  • Di-me-PGE2 alone had little effect on survival.
  • Combination of di-me-PGE2 and indomethacin resulted in lighter tumors.

Takeaway

This study looked at how two drugs affect cancer in mice. One drug helped the mice live longer, while the other drug made it harder for them to survive.

Methodology

Mice were treated with di-me-PGE2 and/or indomethacin, and tumor weight and survival time were measured.

Limitations

The study was limited to specific mouse strains and tumor types, which may not generalize to other cancers.

Participant Demographics

Male WHT/Ht mice were used in the study.

Statistical Information

P-Value

p<0.02

Statistical Significance

p<0.02

Want to read the original?

Access the complete publication on the publisher's website

View Original Publication